BioPharma Credit (BPCR) recently announced that it has entered into an agreement to provide a US$80m senior secured loan to BioDelivery Sciences International (BDSI), a Nasdaq-listed commercial-stage pharma company. BDSI’s main assets include Belbuca, an FDA-approved partial opioid agonist classified as a Schedule III drug, as well as Symproic, an FDA-approved drug for the treatment of opioid-induced constipation (OIC). This agreement represents BPCR’s first investment this year.
03 Jun 2019
BioPharma Credit - Debt and equity investment in BDSI
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPharma Credit - Debt and equity investment in BDSI
BioPharma Credit PLC USD (BPCR:LON) | 87.6 -0.2 (-0.2%) | Mkt Cap: 1,078m
- Published:
03 Jun 2019 -
Author:
Milosz Papst -
Pages:
3
BioPharma Credit (BPCR) recently announced that it has entered into an agreement to provide a US$80m senior secured loan to BioDelivery Sciences International (BDSI), a Nasdaq-listed commercial-stage pharma company. BDSI’s main assets include Belbuca, an FDA-approved partial opioid agonist classified as a Schedule III drug, as well as Symproic, an FDA-approved drug for the treatment of opioid-induced constipation (OIC). This agreement represents BPCR’s first investment this year.